Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 11;29(10):2547–2558. doi: 10.1038/s41591-023-02547-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — Mean fraction of intact, 3′ and 5′ defective HIV-1 proviruses per 10⁶ CD4 + T cells from 39 individuals at ATI start (day 0) (a). The size of the 3’ (b) and 5’ (c) defective HIV-1 reservoir at ATI start (day 0) and after 6, 13 and 25 weeks of ATI among individuals in the four randomization groups (lines at median and IQRs). Placebo/placebo group (n = 10); lefitolimod/placebo (n = 9); placebo/bNAb (n = 10); and lefitolimod/bNAb (n = 11). All weeks are shown, including weeks with no data available. Median change in the 3’ (d) and 5’ (e) defective HIV-1 reservoir between week 6 of the ATI and pre-ATI for the four randomization groups are shown. Data are median and IQRs with the placebo/placebo group as the reference. Placebo/placebo group (n = 10); lefitolimod/placebo (n = 8); placebo/bNAb (n = 9); and lefitolimod/bNAb (n = 9). P values comparing within groups (only P values below 0.05 are shown) and between groups were calculated using the paired two-tailed Wilcoxon test and two-tailed Mann–Whitney test, respectively. ART, antiretroviral therapy; ATI, ART interruption; IQR, interquartile ranges; bNAb, broadly neutralizing antibody.